載入...
Overexpression of topoisomerase II alpha protein is a factor for poor prognosis in patients with luminal B breast cancer
BACKGROUND: The prognostic value and the best method of testing of topoisomerase II alpha (TOP2A) status have not been established in modern tailored therapy based on breast cancer subtype. RESULTS: The frequencies of TOP2A overexpression and TOP2A amplified were 55.8% and 9.5%, respectively. TOP2A...
Na minha lista:
| 發表在: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Impact Journals LLC
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6003555/ https://ncbi.nlm.nih.gov/pubmed/29928479 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25468 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|